BLRX Quote, Financials, Valuation and Earnings

Compugen has a net margin of -117.78% compared to BioLine Rx's net margin of 7.45%. BioLine Rx's return on equity of -160.88% beat Compugen's return on equity of 2.69%.

BioLine Rx has a consensus price target of $4.57, signalling upside risk potential of 4399.18%. On the other hand Compugen has an analysts' consensus of $4.00 which suggests that it could grow by 77.78%. Given that BioLine Rx has higher upside potential than Compugen, analysts believe BioLine Rx is more attractive than Compugen.

BioLine Rx has a beta of 1.458, which suggesting that the stock is 45.758% more volatile than S&P 500. In comparison Compugen has a beta of 2.588, suggesting its more volatile than the S&P 500 by 158.755%.

BioLine Rx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLine Rx pays -- of its earnings as a dividend. Compugen pays out -- of its earnings as a dividend.

BioLine Rx quarterly revenues are $4.9M, which are smaller than Compugen quarterly revenues of $17.1M. BioLine Rx's net income of -$5.8M is lower than Compugen's net income of $1.3M. Notably, BioLine Rx's price-to-earnings ratio is -- while Compugen's PE ratio is 75.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLine Rx is 0.35x versus 3.36x for Compugen. Usually stocks with elevated PS ratios are considered overvalued.

BiomX has a net margin of -117.78% compared to BioLine Rx's net margin of --. BioLine Rx's return on equity of -160.88% beat BiomX's return on equity of --.

BioLine Rx has a consensus price target of $4.57, signalling upside risk potential of 4399.18%. On the other hand BiomX has an analysts' consensus of $7.00 which suggests that it could grow by 812.41%. Given that BioLine Rx has higher upside potential than BiomX, analysts believe BioLine Rx is more attractive than BiomX.

BioLine Rx has a beta of 1.458, which suggesting that the stock is 45.758% more volatile than S&P 500. In comparison BiomX has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.797%.

BioLine Rx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLine Rx pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.

BioLine Rx quarterly revenues are $4.9M, which are larger than BiomX quarterly revenues of --. BioLine Rx's net income of -$5.8M is lower than BiomX's net income of $9.6M. Notably, BioLine Rx's price-to-earnings ratio is -- while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLine Rx is 0.35x versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.

Pluri has a net margin of -117.78% compared to BioLine Rx's net margin of -1804.3%. BioLine Rx's return on equity of -160.88% beat Pluri's return on equity of -438.78%.

BioLine Rx has a consensus price target of $4.57, signalling upside risk potential of 4399.18%. On the other hand Pluri has an analysts' consensus of -- which suggests that it could grow by 640.74%. Given that BioLine Rx has higher upside potential than Pluri, analysts believe BioLine Rx is more attractive than Pluri.

BioLine Rx has a beta of 1.458, which suggesting that the stock is 45.758% more volatile than S&P 500. In comparison Pluri has a beta of 1.664, suggesting its more volatile than the S&P 500 by 66.393%.

BioLine Rx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLine Rx pays -- of its earnings as a dividend. Pluri pays out -- of its earnings as a dividend.

BioLine Rx quarterly revenues are $4.9M, which are larger than Pluri quarterly revenues of $326K. BioLine Rx's net income of -$5.8M is higher than Pluri's net income of -$5.9M. Notably, BioLine Rx's price-to-earnings ratio is -- while Pluri's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLine Rx is 0.35x versus 38.38x for Pluri. Usually stocks with elevated PS ratios are considered overvalued.

XTL Biopharmaceuticals has a net margin of -117.78% compared to BioLine Rx's net margin of -341.36%. BioLine Rx's return on equity of -160.88% beat XTL Biopharmaceuticals's return on equity of -34.34%.

BioLine Rx has a consensus price target of $4.57, signalling upside risk potential of 4399.18%. On the other hand XTL Biopharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 1707.23%. Given that BioLine Rx has higher upside potential than XTL Biopharmaceuticals, analysts believe BioLine Rx is more attractive than XTL Biopharmaceuticals.

BioLine Rx has a beta of 1.458, which suggesting that the stock is 45.758% more volatile than S&P 500. In comparison XTL Biopharmaceuticals has a beta of 1.139, suggesting its more volatile than the S&P 500 by 13.856%.

BioLine Rx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLine Rx pays -- of its earnings as a dividend. XTL Biopharmaceuticals pays out -- of its earnings as a dividend.

BioLine Rx quarterly revenues are $4.9M, which are larger than XTL Biopharmaceuticals quarterly revenues of $162K. BioLine Rx's net income of -$5.8M is lower than XTL Biopharmaceuticals's net income of -$553K. Notably, BioLine Rx's price-to-earnings ratio is -- while XTL Biopharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLine Rx is 0.35x versus -- for XTL Biopharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.